A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate

BACKGROUND: An economic analysis from the perspective of the UK National Health Service (NHS) evaluated the cost effectiveness of lisdexamfetamine dimesylate (LDX) compared with atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder who have had an inadequate response...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimovetz, Evelina A., Beard, Stephen M., Hodgkins, Paul, Bischof, Matthias, Mauskopf, Josephine A., Setyawan, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035654/
https://www.ncbi.nlm.nih.gov/pubmed/27530525
http://dx.doi.org/10.1007/s40263-016-0354-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035654/
https://www.ncbi.nlm.nih.gov/pubmed/27530525
http://dx.doi.org/10.1007/s40263-016-0354-3

Ejemplares similares